14 completed, 4 withdrawn, 3 unknown, 2 suspended. 12 Not applicable, 9 Phase 2, 6 Phase 3, 3 Phase 1.
Follow Placebo oil: new trials by email Literature Review of Placebo oil trials Research Report on Placebo oil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of the Consumption of Cookies Enriched With Plant Proteins and of a Vitamin D Supplement on the Progression of Sarcopenia in the Elderly Vitamin D3 supplement, Protein-enriched biscuits, Control biscuit - Sarcopenia in Elderly, Sarcopenia | Not applicable | Active not recruiting | University of Udine | 74 | 2025-12-01 | 2026-07-27 |
| The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex Cannabidiol (CBD) Oil 300mg, Cannabidiol (CBD) Oil 150mg, Placebo Oil - Cannabidiol Effects, Driving Performance | Phase 1 | Recruiting | West Virginia University | 300 | 2025-06-30 | 2026-10-06 |
| Effects of CBD Oil on Memory Reconsolidation and Trauma-Related Symptoms Trauma Memory Reactivation, Cannabidiol (CBD) Broad-Spectrum Oil, Placebo Oil - Posttraumatic Stress Disorder | Not applicable | Withdrawn | University of Texas at Austin | 2024-08-31 | 2024-01-09 | |
| Improving Pain Disability With the Use of Oral Cannabinoids CBD oil ( MPL-001), CDB+THC oil (MPL-005), Placebo oil - Chronic Pain, Opioid Use | Not applicable | Completed | University Health Network, Toronto | 51 | 2022-11-22 | 2026-07-22 |
| A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia. Medical Cannabis, Placebo Oil - Agitation,Psychomotor, Disruptive Behavior | Not applicable | Terminated | M. H MediCane Ltd. | 24 | 2022-10-12 | 2024-06-27 |
| Impact of CBD-Rich Oil on Aversive Memory Reconsolidation Interoceptive Aversive Memory Reactivation, Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil, Placebo Oil - Anxiety and Fear | Phase 1 / Phase 2 | Unknown | University of Texas at Austin | 96 | 2022-01-01 | 2022-01-19 |
| Lavender Oil Aromatherapy for The Treatment of Acute Anxiety During Bone Marrow Biopsy Procedures Lavender Oil Aromatherapy, Placebo oil, BMAB procedure - Hematologic Diseases | Not applicable | Withdrawn | Case Comprehensive Cancer Center | 2021-08-01 | 2021-11-10 | |
| The HepatoPancreaticoBiliary Resection Arginine Immunomodulation (PRIMe) Trial Active A, Active B, Lipid bolus - Hepatopancreaticobiliary (HPB) Malignancy, Surgery | Not applicable | Completed | Sunnybrook Health Sciences Centre | 45 | 2021-06-16 | 2024-04-03 |
| Effects of Aromatherapy on Patient Satisfaction With Surgical Abortion at Less Than 10 Weeks Gestation Placebo oil, Lavender oil. - Surgical Abortion, Patient Satisfaction | Not applicable | Completed | University of Colorado, Denver | 144 | 2021-05-13 | 2025-08-03 |
| Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose), Placebo Oil - Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Withdrawn | McMaster University | 2021-04-01 | 2021-03-24 | |
| CBD Oil for Reducing Emotional Impact of COVID-19 CBD Isolate, Full Spectrum CBD Oil, Broad-Spectrum CBD Oil - Anxiety Depression, Alcohol Abuse | Phase 2 / Phase 3 | Suspended | University of Texas at Austin | 200 | 2020-12-04 | 2023-11-22 |
| CHI-902 for Treatment of Social Anxiety Disorder CHI-902, Placebo - Social Anxiety Disorder | Phase 2 | Withdrawn | Canopy Growth Corporation | 2020-01-24 | 2020-06-04 | |
| Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder CBD Isolate, CBD Broad Spectrum, Placebo oil - Post Traumatic Stress Disorder | Phase 2 | Suspended | University of Texas at Austin | 150 | 2020-01-15 | 2023-11-22 |
| High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial placebo Oil, 25-Hydroxyvitamin D - HIV-1-infection, Hypovitaminosis D | Phase 3 | Completed | University of the Punjab | 95 | 2019-02-15 | 2022-04-11 |
| Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease MediCabilis CBD Oil, Placebo Oil - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 3 | Unknown | Gold Coast Hospital and Health Service | 17 | 2019-01-09 | 2023-04-03 |
| The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses Triheptanoin, Placebo Oil - Tarui Disease, Debrancher Deficiency | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 3 | 2018-08-15 | 2024-02-22 |
| The Effect of n-3 PUFA Plant Oil Intake on Human Metabolism Placebo oil, Echium oil, Mixed oil - Hyperlipidemias | Not applicable | Unknown | Huazhong University of Science and Technology | 150 | 2018-06-01 | 2018-05-09 |
| The Effect of Cannabis on Dementia Related Agitation and Aggression Cannabis, Placebo oil - Agitation Related to Dementia | Phase 2 | Completed | TO Pharmaceuticals | 64 | 2017-12-07 | 2022-03-08 |
| The Omega-3 Fatty Acid Paediatric Depression Trial Omega 3 fatty acid, Placebo oil - Depression | Phase 3 | Completed | Gregor Berger | 257 | 2017-04-28 | 2023-04-06 |
| Triheptanoin in Mc Ardle Triheptanoin, Placebo oil - Glycogen Storage Disease Type V | Phase 2 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 12 | 2016-11-16 | 2025-09-04 |
Showing 20 of 27. Sign in to see all of them.
Anxiety Disorders (3) · Marijuana Abuse (3) · Dementia (2) · Glycogen Storage Disease Type V (2) · Phobia, Social (2) · Stress Disorders, Post-Traumatic (2) · Agoraphobia (1) · Alcoholism (1) · Alzheimer Disease (1) · Amyotrophic Lateral Sclerosis (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Chronic Pain (1) · Cognitive Dysfunction (1) · Color Vision Defects (1)
University of Texas at Austin (4) · Copenhagen University Hospital, Rigshospitalet (2) · Aromtech Ltd. (1) · Canopy Growth Corporation (1) · Case Comprehensive Cancer Center (1) · Gold Coast Hospital and Health Service (1) · Gregor Berger (1) · Huazhong University of Science and Technology (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · M. H MediCane Ltd. (1) · McMaster University (1) · Pennington Biomedical Research Center (1) · Sunnybrook Health Sciences Centre (1) · TO Pharmaceuticals (1) · The George Washington University Biostatistics Center (1)
United States (9) · Canada (4) · Denmark (2) · Israel (2) · Australia (1) · China (1) · Finland (1) · France (1) · Ireland (1) · Italy (1) · Pakistan (1) · Switzerland (1) · United Kingdom (1)
Michael J Telch, Ph.D. (3) · Alessandro Cavarape, M.D. (1) · Baukje De Roos, PhD (1) · Hance Clarke, MD, PhD (1) · Karen L Madsen, MD (1) · Klaus Schmeck, MD (1) · Leanne Free, MD (1) · Mark Ware, MD (1) · Menachem Miodovnik, MD (1) · Michael Hutchinson, MB, FRCP (1) · Michael J. Telch, PhD (1) · Michael Van Ameringen, MD, FRCPC (1) · Neta Rimmerman, PhD (1) · Paul Karanicolas, MD, PhD (1) · Richard Lee, MD (1)
PMID 12122118, PMID 12210323, PMID 1281472, PMID 15293280, PMID 15781190, PMID 1580445, PMID 16602102, PMID 16763895, PMID 16763896, PMID 17584774, PMID 1824792, PMID 18401027, PMID 18541798, PMID 18645163, PMID 18929906, PMID 19237700, PMID 20357282, PMID 20393176, PMID 20631546, PMID 20655781, PMID 2199596, PMID 2295969, PMID 23010094, PMID 23031366, PMID 23507172, PMID 23981773, PMID 24453079, PMID 25272951, PMID 25641922, PMID 25832663, PMID 26255073, PMID 26652229, PMID 26812512, PMID 28932990, PMID 29458842, PMID 31520525, PMID 31719072, PMID 31827448, PMID 33660625, PMID 3447177, PMID 34532852, PMID 35811050, PMID 36148467, PMID 36154908, PMID 37425294, PMID 37858617, PMID 38580363, PMID 40061518, PMID 40894517, PMID 41481294
2014 (1), 2016 (1), 2017 (1), R01DA058678 (1), U10HD021410 (1), U10HD027869 (1), U10HD027915 (1), U10HD027917 (1), U10HD034116 (1), U10HD034136 (1), U10HD034208 (1), U10HD036801 (1), U10HD040485 (1), U10HD040500 (1), U10HD040512 (1)